Vericel beats Q1 revenue on MACI, burn care growth, lifts 2026 sales outlook

Vericel

07/05/2026 12:55

Overview

US advanced therapies firm's Q1 revenue rose 30%, beating analyst expectations

Gross margin improved to 72% in Q1, up from 69% a year earlier

Company raised 2026 revenue guidance by $10 mln to $326-$336 mln

Outlook

Vericel raises 2026 revenue guidance to $326-$336 mln from $316-$326 mln

Company increases 2026 MACI revenue guidance to $282-$288 mln from $280-$286 mln

Vericel lifts 2026 Burn Care revenue guidance to $44-$48 mln from $36-$40 mln

Result Drivers

MACI GROWTH - MACI revenue rose 22% in Q1, with record biopsies, implants and surgeon participation

BURN CARE SURGE - Burn Care revenue grew 91% in Q1, with Epicel revenue up 119%

EXPENSES UP - Operating expenses increased due to higher headcount, MACI sales force expansion and new facility costs

Company press release: ID:nGNX7NwN6V

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$68.43 mln
$63.64 mln (8 Analysts)
Q1 EPS
-$0.12
Q1 Net Income
-$6.30 mln
Q1 Adjusted EBITDA
$9.56 mln
Q1 Gross Margin
72.00%
Q1 Gross Profit
$49.27 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)